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PURPOSE:  Brugada syndrome is an inherited cardiac arrhythmia disorder characterized by ST 
segment elevation in leads V1-V3 on an electrocardiogram (ECG). The main symptoms of this 
condition are syncope and sudden cardiac death. Medical management for symptomatic patients 
is an implantable cardioverter defibrillator (ICD). Research has shown that cardiac patients who 
have an ICD experience a decreased quality of life. However, limited studies have been done on 
the impact of Brugada syndrome on patient quality of life let alone the impact of medical 
management in this patient population. The purpose of this study was to understand how 
Brugada syndrome affects quality of life and if there is any difference between those with an 
ICD and those without one. The public health significance of this project is to further the 
understanding of the impacts of medical management in a specific patient population.  
METHODS: Participants were recruited from a multigenerational family with Brugada 
syndrome where a mutation has been identified in the gene GPD1L. A questionnaire was 
developed to ascertain medical management decisions. Additionally, the 36-Item Short Form 
Health Survey (SF-36v2) was used to assess quality of life.  
RESULTS:  A total of 17 participants agreed to enroll in the study with an age range of 36-89 
years. Ten of the seventeen had the family mutation in GPD1L with seven of these ten displaying 
the Brugada phenotype on an ECG. Only three participants had an ICD and one participant was 
considering the option in the near future. The main reasons for choosing an ICD were either due 
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 v 
to a sense of inevitability and necessity or for family benefit. There was no difference in quality 
of life between those with the familial mutation and those without. There was also no difference 
observed between asymptomatic and symptomatic individuals with the mutation. Those with an 
ICD had a lower MCS than those without an ICD (p-value 0.013) with no other significant 
differences observed.   
CONCLUSION:  Reasons underlying ICD decision-making are similar to those seen in other 
studies, indicating that Brugada patients’ experiences are similar to other patient groups with an 
ICD. There was no statistical difference in quality of life between those with and those without a 
genetic diagnosis or those with and without symptoms. The difference between those with and 
without an ICD indicates that medical management does impact quality of life, adding more 
evidence to support there is a significant psychosocial aspect to Brugada syndrome management.  
Additional research is needed to better address the specific needs of this patient population.  
 
 
 
 vi 
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PREFACE 
 
This project could not have come to fruition without the family members who so willingly and 
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that would benefit the understanding of Brugada syndrome both in the medical community and 
for others living with the condition.  
 I would also like to thank my family and friends for all of their support during my 
graduate studies. I could not have made it these past two years without my biggest fan and 
supporter, Justin Richards. Thank you for letting me pursue my dreams and holding down the 
fort. To quote the student before me, here’s to a lifetime of weekends! To my dear friend 
Meagan Smith, I could not have made it through this without you. Here’s to the continuation of a 
lifelong friendship. To my families back in Ohio, thank you for all the phone calls, visits, and 
prayers. By His grace, I have made it through this season of my life.  
 To Dr. Barry London and his research nurse, Rebecca Gutmann, thank you for taking me 
under your wing and instilling within me a new found love of cardiovascular genetics. It was a 
little overwhelming at first, but in the end it was one of the best experiences of my life. To my 
program directors, Robin Grubs and Betsy Gettig, thank you for recognizing the potential inside 
of me and granting me the honor of being in this program. Here’s to the celebration of a new 
colleague.  
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1.0  INTRODUCTION 
Brugada syndrome is a cardiac condition characterized by a structurally normal heart but 
abnormal heart beats (arrhythmias). The hallmarks of Brugada syndrome are right bundle branch 
block (RBBB) and  persistent ST segment elevation in the precordial leads V1-V3 of an 
electrocardiogram (ECG)1,2. It is estimated that approximately 1 in 1,000 individuals has the 
condition3. Due to the increased risk for arrhythmias, patients with Brugada syndrome are at an 
increased risk for syncope and sudden cardiac death4. Approximately 30% of individuals with 
Brugada syndrome have an identifiable genetic mutation  in one of eight currently known genes5. 
The majority of mutations are identified in SCN5A which was the first gene shown to be 
associated with the condition6
The only proven therapy for  preventing sudden cardiac death in these patients is an 
implantable cardioverter defibrillator
.  
4. Current management recommendations are that any 
individual with Brugada syndrome who has a past history of syncope or aborted sudden cardiac 
death receive an ICD4. However, controversy surrounds recommendations for patients with the 
condition who have the characteristic ECG pattern but have never had clinical symptoms7
ICDs are used to treat patients with a variety of underlying heart issues such as heart 
failure, prior history of myocardial infarction, ischemic cardiomyopathy and Brugada syndrome 
among many others. Research has shown that living with an ICD can have a significant impact 
.   
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on quality of life8. While the ICD may provide a sense of comfort to some, others experience 
anxiety and depression leading to a lower quality of life overall. The relationship between ICDs 
and quality of life in Brugada syndrome patients has only been studied by one research group in 
France at the time this thesis document was written9
The purpose of this study was to evaluate the impact of an ICD on the quality of life in 
patients affected with Brugada syndrome and what factors influence a patient’s decision making 
to accept or decline an ICD. To this end, the 36-Item Short Form Health Survey (SF36v2) was 
administered to a multigenerational family with Brugada syndrome and an identifiable mutation 
in GPD1L to assess quality of life between three groups: those with and without the genetic 
mutation, those with the mutation who have symptoms and those who do not, and those with the 
mutation and symptoms who have an ICD and those without one.   A questionnaire was 
developed and implemented to assess reasons for choosing or declining an ICD as well as 
demographic information.  
.  
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2.0  BACKGROUND  
2.1 BRUGADA SYNDROME HISTORY  
Brugada syndrome is an inherited cardiac arrhythmia disorder that was first characterized by 
Pedro and Josep Brugada in 19921. These patients have structurally normal hearts with 
ventricular arrhythmias characterized by right bundle branch block and persistent ST segment 
elevation in the precordial leads V1-V3 of an electrocardiogram (ECG)1,2. In 1998, the first 
underlying genetic mechanism of the disease was identified as mutations in the sodium channel, 
voltage-gated, type V, alpha subunit (SCN5A)10
 
. Since that time, mutations in eight different 
genes have been shown to cause Brugada syndrome and there is now a clearer understanding of 
both the molecular genetics and cellular mechanisms of disease.  
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Figure 1: Cardiac Electrical Cycle 
2.2 CLINICAL FEATURES 
2.2.1 Electrocardiographic Findings 
The hallmark of Brugada syndrome is the characteristic patterns observed on an 
electrocardiogram. An electrocardiogram is a medical test used to record the electrical activity of 
the heart. Electrodes are placed at precise locations on the body including both arms, both legs, 
and the chest. There are usually ten of these electrodes in the standard 12-lead ECG. Each lead 
represents a tracing of the voltage between two or more of the electrodes. For Brugada 
syndrome, the electrodes or leads V1 through V3 are important for diagnosing the condition. V1 
is placed in the fourth intercostal space between the fourth and fifth ribs just to the right of the 
sternum. V2 is also placed in the fourth intercostal space just to the left of the sternum. V3 is 
placed between V2 and V4, which is in the fifth intercostal space in the midclavicular line11. 
Placing V1 and V2 one intercostal space higher (in the third intercostal space) increases the 
sensitivity of the ECG in detecting the Brugada phenotype12
  
.     
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Each beat of the heart on an ECG can be broken down into five deflections: P, Q, R, S 
and T (see Figure 111). The cardiac cycle begins with a P wave followed by a QRS complex and 
ending with a T wave11
The Brugada ECG pattern was first reported as right bundle branch block (RBBB) and 
persistent ST segment elevation in the precordial leads V1-V3 of an ECG
. The ST segment represents the period of zero potential between 
ventricular depolarization and repolarization. On the ECG, it is the time from when the QRS 
complex ends and the T wave begins.  
1,2. More specifically, 
when the QRS complex ends, there is positive deflection known as prominent J wave. This is 
followed by an elevated down-sloping ST segment with a negative T wave and normal to short 
QT intervals. Although this is the typical description of a Brugada type ECG, there are in fact 
three patterns of Brugada syndrome each characterized by distinctive ECG findings(Figure 2)4,13–
15,23
 
.  
The Type 1 ECG is the classic Brugada pattern as described by Brugada et al in 19921. In 
this pattern, there is a ≥2mm J point elevation followed by a downsloping or coved ST segment 
Figure 2: The Three Brugada ECG Patterns 
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and a negative (inverted) T wave13. The Type 2 pattern is also referred to as the saddleback 
type4. It also shows a ≥2mm J point elevation but has a gradually descending ST segment that 
does not reach the baseline and is elevated ≥1mm which causes the saddleback appearance4,15. It 
also is characterized by a positive (upward) or biphasic T wave. Finally, the Type 3 pattern is 
characterized by a smaller magnitude of ST segment elevation, ≤1mm, with either a saddleback 
or coved type appearance and J point elevation ≥2mm4,13,16. Table 1 lists each type of Brugada 
ECG pattern and characteristic ECG findings in leads V1-V317
 
.  
Table 1: Characteristics of Brugada ECG Patterns in Leads V1-V3 (Adapted from Wilde et al. 2002) 
 Type 1 Type 2 Type 3 
J-point ≥2mm ≥2mm ≥2mm 
T-wave Negative Positive or biphasic Positive 
ST-T configuration Coved type Saddleback Saddleback or coved 
ST segment 
Downsloping/ 
gradually descending Elevated≥1mm Elevated≤1mm 
 
In addition to ECG abnormalities discussed, RBBB is also associated with Brugada 
syndrome. The presence of RBBB was at one time necessary for the diagnosis of the condition, 
however, not all individuals have RBBB and thus it is no longer a necessary factor for 
diagnosis4,17. Right bundle branch block is an interference in the electrical conduction of the 
heart11. Other ECG abnormalities that may be seen in Brugada syndrome include: QRS axis 
deviation, P wave enlargement, PQ prolongation, atrioventricular (AV) node dysfunction, sinus 
node dysfunction, and occasionally QTc prolongation15. All of these features represent signs of 
conduction defects.  
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2.2.2 Physical Manifestations 
Brugada syndrome is not usually associated with structural heart disease1,2. All symptoms and 
manifestations of the disease are due to cardiac arrhythmias. The ST segment elevation in 
Brugada syndrome is associated with a high risk for ventricular arrhythmias1,2,13. This includes 
both ventricular tachycardia (VT) and ventricular fibrillation (VF). VT is a rapid but regular 
heartbeat originating in the ventricles. VF is a rapid and irregular heartbeat. When the arrhythmia 
occurs for a few seconds before spontaneously resolving, it can lead to the clinical symptoms of 
Brugada syndrome. These symptoms are the same as individuals in the general population who 
experience VT/VF: palpitations, lightheadedness and dizziness, and syncope13–15,18. If the 
arrhythmia does not spontaneously resolve, it can lead to sudden cardiac death. In addition to VT 
and VF, supraventricular arrhythmias such as atrial fibrillation can occur in 15 to 20% or patients 
with Brugada syndrome15
Most patients with Brugada syndrome never experience any symptoms
.  
15. In those who 
do, the most  common symptoms are syncope and sudden cardiac death19. The percentage of 
clinically affected individuals with at least one cardiac arrest before age 60 is 10-15%, 
supporting the fact that the majority of patients remain asymptomatic3. The first symptoms 
usually occur in the third and fourth decade of life4. It is not common for symptoms to appear in 
childhood, however, some studies indicate that this early onset of symptoms correlates with a 
more aggressive form of the disease3.  Many patients with Brugada syndrome are identified after 
an aborted sudden cardiac death and screening of at risk family members20. A study in 1998 by 
Brugada et al. on long-term outcome of patients with Brugada syndrome demonstrated that both 
symptomatic and asymptomatic patients had a similar risk for sudden cardiac death (34% versus 
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27% respectively)20. Since then, many Brugada registries have been created with the purpose of 
identifying the annual incidence of life-threatening arrhythmias. However, many of these 
registries disagree about the annual incidence. Table 2 below summarizes the findings of the 
different Brugada registries21
 
.  
Table 2: Comparison of Brugada Syndrome Registries (Adapted from Priori et al. 2012) 
 
Brugada et al. 
200322
FINGER
 
23 PRELUDE 21 Delise et al. 
2011
 24
Number of patients 
 
443 967 308 320 
Number with syncope before 
enrollment  
100 (23%) 313(32%) 64 (21%) 105 (34%) 
Number with aborted Sudden 
Cardiac Death (SCD) before 
enrollment  
80 (18%) 62 (6.4%) Not available 
Excluded from 
the study 
Number with Spontaneous 
Type 1 ECG  
391 (71%) 437 (45%) 171 (56%) 174 (54%) 
Arrhythmic events at follow-
up  
65 (14.7%) 51 (5.2%) 14 (4.5%) 17 (5.3%) 
Annual arrhythmic event rate 
in symptomatic patients 
4.1% 
7.7% in patients with 
aborted SCD; 
1.9% in patients with 
syncope 
1.5% 3.0% 
Annual arrhythmic event rate 
in asymptomatic patients 
Not available  0.5% Not available 0.8% 
 
2.2.3 Risk Factors  
For some of the inherited cardiac arrhythmia conditions like Long QT syndrome, clear risk 
factors have been linked to increased risk for symptoms and avoidance of these factors decreases 
risks. In Brugada syndrome, arrhythmias typically occur at rest or during sleep and as such no 
clear prevention strategies exist. There have been reports of avoidable risk factors such as 
cocaine use, large meals, and excessive alcohol consumption4. In addition, some medications 
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such as class 1C antiarrhythmic drugs and tricyclic antidepressants have also been shown to 
induce arrhythmias in Brugada syndrome patients (more information in section 2.6.4 Agents and 
Circumstances to Avoid). Fevers also increase the risk of arrhythmia in Brugada syndrome 
patients and precautions should be taken during periods of illness25
Perhaps one of the largest risk factors associated with Brugada syndrome is male gender. 
It is estimated that 80% of  Brugada patients in Western countries and 90% of patients in Asian 
countries are male
.  
26. Furthermore, the clinical phenotype is 8 to 10 times more prevalent in 
males than in females27. Possible explanations for this phenomenon revolve around the sex 
hormone testosterone and modulation of cardiac potassium currents (Ito)26,27
2.3 EPIDEMIOLOGY 
.   
Sudden cardiac death is a major public health burden. Each year in the United States, 
approximately 300,000 deaths are a result of sudden cardiac death28. The overall number of cases 
of sudden death in young people (e.g. under the age of 40) is not well known as no clear unifying 
diagnoses exists to allow these numbers to be tracked. Most cases of sudden cardiac death in the 
young occur in men who die during sleep or at rest29.Where sudden cardiac death in individuals 
over age 40 is largely attributed to coronary artery disease, sudden cardiac death in young people 
remains largely unexplained as most cases do not have an explanation that can be found by 
autopsy. Up to 40% of these autopsy-negative sudden cardiac deaths can be attributed to sudden 
arrhythmic death syndromes including Brugada syndrome30. Brugada syndrome itself is 
10 
 
estimated to be responsible for anywhere from 4% to 20% of sudden deaths in individuals with 
no evidence of structural heart disease4
There is also a link between Brugada syndrome and sudden infant death syndrome 
(SIDS). SIDS is defined as the death of an infant under the age of 1 year that remains 
unexplained after a thorough case investigation including medical autopsy, death scene 
investigation and detailed review of the clinical history
. 
31.  Approximately 10% of SIDS cases 
can be attributed to sudden arrhythmic death syndromes including Brugada syndrome31. Of these 
cases, about half involve mutations in SCN5A31. The first report of the connection between 
Brugada syndrome and SIDS was in 2000 where a mutation in SCN5A was found to be 
associated with SIDS and sudden cardiac death in young children in one family32.  For these 
reasons, Brugada syndrome as well as any of the inherited arrhythmia syndromes should be 
considered in any case of sudden unexplained death especially in children and young adults30,32
The overall prevalence of Brugada syndrome is unknown but is estimated to be 0.10% or 
1 individual per 1,000 worldwide with a lower frequency in Western countries and higher 
frequency in Southeast Asia
.  
3,13. Due to the variable expressivity and reduced penetrance in 
Brugada syndrome, more precise estimates of prevalence are difficult to obtain for most 
countries4. Brugada syndrome is endemic in Thailand and the Philippines where it is the second 
cause of death in young men occurring particularly during sleep13,33. The average age of 
diagnosis or sudden death in Brugada syndrome is 41 ± 15 years4. However, the youngest patient 
diagnosed with Brugada syndrome was 2 days old and the oldest patient was 84 years old4.  
11 
 
2.4 GENETICS 
The first gene identified as being causative of Brugada syndrome was SCN5A10
Table 3: Brugada Syndrome Genes  
. To date, there 
are currently eight confirmed genes associated with Brugada syndrome that demonstrates locus 
heterogeneity (Table 3).  The majority of the genes associated with Brugada syndrome encode 
for ion channel proteins hence why Brugada syndrome is often described as an inherited 
channelopathy.  
Brugada 
Type 
Gene 
Symbol 
Chromosomal 
Locus 
Protein Name Effect of Mutation 
BrS1 SCN5A 3p22.2 Cardiac sodium channel alpha subunit Loss of function 
BrS2 GPD1L 3p22.3 Glycerol-3-phosphate dehydrogenase 1-like  Loss of function 
BrS3 CACNA1C 12p13.3 Voltage-dependent L-type calcium channel subunit alpha-1C Loss of function 
BrS4 CACNB2 10p12.33-p12.31 
Voltage-dependent L-type calcium channel 
subunit beta-2 
Loss of function 
BrS5 SCN1B 19q13.1 Sodium channel subunit beta-1 Loss of function  
BrS6 KCNE3 11q13.4 Potassium voltage-gated channel subfamily E member 3 Gain of function 
BrS7 SCN3B 1q23.3 Sodium channel subunit beta-3 Loss of function 
BrS8 HCN4 15q24.1 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Loss of function  
 
Mutations in these genes lead to Brugada syndrome by altering the electrical potential of 
cardiac myocytes34. Mutations in SCN5A, GPD1L, SCN1B and SCN3B lead to a reduction in 
sodium current (INa)34,35. Mutations in KCNE3 lead to an increase in potassium current (Ito) 
which increases total cellular charge and leads to Brugada syndrome36. Mutations in CACNA1C 
and CACNB2 lead to a reduction in the calcium current (ICaL and ICa respectively). In addition, 
mutations in these two calcium channel subunits can cause a decreased QT interval on the 
ECG37.  Thus patients with mutations in these genes are often considered to have both Brugada 
12 
 
syndrome and Short QT syndrome34,37. Mutations in HCN4 may induce Brugada syndrome by 
altering potassium current (If)38
Mutations in SCN5A are also associated with Long QT syndrome type 3. However, these 
mutations tend to be gain of function rather than loss of function
.  
19
All known genes associated with Brugada syndrome are inherited in an autosomal 
dominant fashion. There have been no descriptions of de novo mutations or germline mosaicism 
and as such extensive evaluation of the family for disease is recommended
.  There is clinical overlap in 
the presenting symptoms (e.g. syncope and sudden cardiac death); however the findings on an 
ECG are the distinguishing features. In Long QT syndrome, there is a prolongation of the QT 
interval that is usually not seen in Brugada syndrome. There are families with both Long QT and 
Brugada syndrome with one SCN5A mutation.  
14
Brugada syndrome also demonstrates reduced penetrance and variable expressivity. Not 
every person with a mutation will show signs or symptoms of the condition and there can be 
variability in the phenotype within a family.  
.  Siblings of an 
affected individual have a 50% risk to have also inherited the disease-causing mutation. 
Likewise, children of an affected individual have a 50% chance of inheriting the mutation and 
being at risk for Brugada syndrome. There is a 50% chance that either parent has the disease 
causing mutation. It is important to determine which parent has the mutation as his or her family 
members would also be at risk.  
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2.5 DIAGNOSIS  
2.5.1 Clinical Diagnosis  
The following table lists the diagnostic criteria for a clinical diagnosis of Brugada 
syndrome4,14,17
Table 4: Clinical Diagnosis of Brugada Syndrome 
: 
Definitive diagnosis of Brugada syndrome: 
ECG Finding 
Type 1 Pattern (elevation of the J wave ≥2mm with a negative T wave and 
coved type/gradually descending ST segment) in more than one right 
precordial lead (V1 to V3) in the presence or absence of sodium channel 
blocker. No confounding factors accounting for ECG abnormality. 
AND 
At least one of 
the following: 
• Documented VF 
• Polymorphic VT 
• Family history sudden cardiac death <45 years old 
• Coved-type ECGs in family members 
• Induciblity of VT with programmed electrical stimulation 
• Syncope or nocturnal agonal respiration 
AND/OR 
Mutation in: SCN5A, GPD1L, CACNA1C, CACNB2, SCN1B, KCNES, SCN3B, or HCN4 
Suspected diagnosis of Brugada syndrome:  
ECG Finding 
Type 2 ECG Pattern (elevation of the J wave ≥2 mm with a positive or 
biphasic T wave and saddleback ST segment elevated ≥1 mm) in more than 
one right precordial lead under baseline conditions with conversion to Type 1 
pattern following challenge with a sodium channel blocker 
OR 
ECG Finding 
Type 3 ECG Pattern (elevation of J wave ≥2 mm with a positive T wave and 
coved/saddleback ST segment elevated ≤1mm) in more than one right 
precordial lead under baseline conditions with conversion to Type 1 pattern 
following challenge with a sodium channel blocker 
Inconclusive for diagnosis of Brugada syndrome: 
ECG Finding 
Type 3 ECG Pattern in more than one right precordial lead under baseline 
conditions with conversion to Type 2 ECG pattern following challenge with a 
sodium channel blocker  
14 
 
2.5.2 Use of Sodium Channel Blockers to Unmask Brugada Syndrome 
Sodium channel blockers have been shown to amplify or unmask the Brugada Type 1 ECG 
pattern4,17,39,40. These drugs are usually prescribed to treat arrhythmias through impairment of 
conduction of sodium ions through sodium channels. However, when given to patients with 
Brugada syndrome, sodium channel blockers can provoke typical ST segment elevation15. They 
work by producing strong use-dependent blocking of fast sodium current (INa) secondary to their 
slow dissociation from the sodium channels13
Many patients in whom a diagnosis of Brugada syndrome has previously been made do not 
show consistent characteristic findings on an ECG. With this in mind, it can be difficult to 
identify at risk family members or infer if an individual with a Type 2 or Type 3 ECG pattern 
really has Brugada syndrome when those with the condition do not consistently display the Type 
1 pattern. In these situations, a diagnostic challenge with a  sodium channel blocker may be used 
to induce the Type 1 pattern
.  
4,40.  The types of drugs used include class 1A and class 1C 
antiarrhythmic drugs such as flecainide, procainamide, ajmaline, and pilsicainide4. Descriptions 
of the protocol and precautions have been described elsewhere4,17,40–42
2.5.3 Genetic Testing 
.  
Genetic testing for Brugada syndrome is not necessary to establish the diagnosis. However, 
genetic testing can be used to confirm the diagnosis and is useful for the identification of at-risk 
family members5,13,14. In 2011, the Heart Rhythm Society published a set of consensus guidelines 
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on the role of genetic testing for channelopathies and cardiomyopathies, including Brugada 
syndrome. The recommendations for Brugada syndrome genetic testing are as follows5
1. Comprehensive or BrS1 (SCN5A) targeted Brugada syndrome (BrS) genetic 
testing can be  us eful for any patient in whom a cardiologist has established a 
clinical index of suspicion for BrS based on examination of the patient’s clinical 
history, family history, and expressed electrocardiographic (resting 12-lead ECGs 
and/or provocative drug challenge testing) phenotype. 
:  
2. Genetic testing is n ot in dicated in the setting of an isolated type 2 or type 3 
Brugada ECG pattern. 
3. Mutation-specific genetic testing is reco mmended for family members and 
appropriate relatives following the identification of the BrS-causative mutation in 
an index case. 
These recommendations took into consideration the low yield of genetic testing at this 
time. On average, genetic testing for Brugada syndrome yields a disease causing mutation 30% 
of the time5. The remaining 70% of Brugada syndrome cases remain unexplained genetically. 
Table 5 illustrates the eight current known genes involved with Brugada syndrome and the 
percentage of disease caused by each gene14,43
Table 5: Frequency of Genetic Mutations Causing Brugada Syndrome 
.  
Gene Frequency 
SCN5A 15-30%6
GPD1L 
 
Rare 
CACNA1C <5% 
CACNB2 <5% 
SCN1B Rare 
KCNE3 Rare 
SCN3B Rare 
HCN4 Very Rare 
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The majority of patients with a genotype positive case of Brugada syndrome have a 
mutation in SCN5A. For this reason, the proposed testing strategy is to start with sequence 
analysis of SCN5A. If no mutation is found, sequence analysis of CACN1C, SCN1B, KCNE3, and 
SCN3B may be considered with the underlying expectation of low yield14
2.5.4 Identification of At-Risk Family Members  
. HCN4 genetic testing 
is currently not available in the United States. GeneDx currently offers a Brugada syndrome 
panel that screens for SCN5A, CACN1C, CACNB2, GPD1L, SCN1B, KCNE3, and SCN3B with a 
quoted detection rate of 26-41%.  
If there is a known mutation causing Brugada syndrome in the index case, cascade screening of 
first degree family members to identify those who also carry the mutation and are at risk of 
developing symptoms5,44
In the absence of a known genetic mutation, the only methods available for the 
identification of at-risk family members include ECG and provocative drug testing
. This method allows accurate identification of which family members 
are at risk for Brugada syndrome. Further testing such as an electrocardiogram or provocative 
drug-testing may be useful in risk stratification.   
40. Since 
Brugada syndrome is inherited in an autosomal dominant pattern of inheritance, first-degree 
relatives have up to a 50% chance of being affected.  
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2.6 MANAGEMENT  
2.6.1 Risk Stratification  
Management of Brugada syndrome depends on accurate risk stratification and the ability to 
identify patients at high risk for an arrhythmic event. Unfortunately, this area remains a source of 
debate among medical professionals7,21–24,45–47. All studies agree that patients at the highest risk 
for an arrhythmic event are those with a prior history of symptoms: aborted sudden cardiac 
death, syncope or documented history of VT4. Controversy ensues when discussing risk 
stratification of asymptomatic patients with a Type 1 ECG pattern. Brugada et al. described it 
well in a 2011 publication in Heart Rhythm: “In all series, [asymptomatic patients with a Type 1 
ECG] has a risk between 0.5% and 3% per year of having an arrhythmic event. This event will 
occur in about 50% of cases as a ventricular fibrillation without pervious syncopal warning. 
Mean age at which symptoms occur is 40 years. Accepting even the lowest published risk, a 10% 
event rate at 20-year follow-up in otherwise healthy patients is unacceptable. Waiting for a 
syncopal episode in order to react is condemning at least 50% of these patients to death47
Brugada et al. proposed that electrophysiologic (EP) testing can be a useful tool to predict 
which asymptomatic patients are at high risk
.” 
22,47. In contrast, Priori et al. in the PRELUDE study 
found that EP testing was unable to identify those patients at high risk and proposed instead that 
other features such as QRS fragmentation  and ventricular effective refractory period <200 ms as 
tools to identify high risk patients21. The FINGER study also reached a similar conclusion as 
PRELUDE as their study population showed no correlation between EP testing and prediction of 
life-threatening events at follow-up23.  In addition, the FINGER study showed that factors such 
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as family history of SCD and presence of a SCN5A mutation were not predictive of arrhythmic 
events. Despite the controversy, EP testing may still be an effective tool for risk stratification and 
selection of patients for ICD implantation4
2.6.2 Treatment of Manifestations: ICD  
.  
The only effective therapy in Brugada syndrome is an implantable cardioverter defibrillator 
(ICD)4. The Second Consensus Report about Brugada syndrome established the 
recommendations for ICD implantation in patients4
Several studies have examined the outcome of Brugada patients treated with an ICD
.  Currently, only individuals with a past 
history of aborted sudden death are considered to be at risk for another event and are 
recommended to have an ICD. Also, any individual with a history or syncope and a spontaneous 
type 1 ECG pattern should have an ICD. Situations where evidence weighs in favor of an ICD 
include history of syncope and a type 1 ECG pattern revealed by sodium channel blocker drug 
testing or spontaneous type 1 ECG pattern with no history of symptoms and inducible for 
ventricular fibrillation or tachycardia. As discussed in section 2.6.1, EP testing for risk 
stratification remains controversial but can be useful to identify asymptomatic patients most 
likely to experience an arrhythmic event and benefit from an ICD. There is much debate on 
management for asymptomatic individuals who do not meet recommendation criteria for an ICD.  
48–51. 
These studies demonstrate that in addition to proper risk stratification, the potential for adverse 
effects of an ICD are significant. One of the most important adverse effects to consider is the rate 
of inappropriate shocks. The following table was adapted from Veltman et al. and demonstrates 
the annual rates of inappropriate ICD shock from different studies49.  
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Table 6: Appropriate and Inappropriate ICD therapy in Patients with Brugada Syndrome 
 
Patients 
(n) 
Patients with 
appropriate 
ICD therapy 
(%) 
Annual rate of 
appropriate 
ICD therapy 
(%/year) 
Patients with 
inappropriate 
ICD therapy 
(%) 
Annual rate of 
inappropriate  
ICD therapy 
(%/year) 
Bordachar et al.52 29  3 (10.5%) 3.9% Not available Not available 
Daoulah et al.50 25  3(12%) 3.5% 3(12%) 3.5% 
Kharazi et al.53 12  2 (17%) 7.2% 5 (42%) 18% 
Holst et al.51 35   9(26%) 6.6% 3(8%) 2.2% 
Sacher et al.54 220   18 (8%) 2.5% 45 (20%) 6.3% 
Sarkozy et al.55 47  7 (15%) 3.8% 17 (36%) 9.1% 
Veltmann et al.49 61   7 (12%) 2.9% 5 (8%) 2.1% 
 
Causes of inappropriate ICD shocks in this patient population can be attributed to 
supraventricular tachycardia, lead malfunction, double counting, external noise detection, and 
younger age of patients. The physical activity of younger patients is higher and therefore the 
occurrence of sinus tachycardia is increased in this population which can lead to inappropriate 
ICD discharge49. Veltmann et al. recommended programming Brugada syndrome patients’ ICDs 
at a single, high-rate VF zone to reduce inappropriate shocks related to supraventricular 
tachycardia49
2.6.3 Prevention of Primary Manifestations: Anti-Arrhythmic Medication  
.  
Brugada syndrome is an inherited channelopathy caused by genetic alterations to ion channels, 
and as such pharmacological treatment is focused on rebalancing the ion channel current. As 
described previously, class 1A and class 1C antiarrhythmic drugs such as flecainide can unmask 
the Brugada ECG pattern and induce VT/VF and are not an effective treatment for these patients. 
Other common antiarrhythmic medicines such as beta-blockers and amiodarone have been 
shown to be ineffective20. In one study, quinidine has been shown to prevent VF induction in 
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patients with Brugada syndrome56.  This medicine works by depressing outward potassium 
current (Ito). There are some concerns related to quinidine therapy as some of the side effects 
include the potential for QT prolongation and torsade de pointes56,57
2.6.4 Agents and Circumstances to Avoid  
. There is not enough long-
term data at this point in time to support quinidine therapy alone instead of ICD placement in 
Brugada syndrome patients.  
Several different agents and circumstances have been demonstrated to unmask the Brugada ECG 
manifestations and may cause VT/VF. These include sodium channel blockers, a febrile state, 
vagotonic agents, α-adrenergic agonists, β-adrenergic blockers, tricyclic or tetracyclic 
antidepressants, a combination of glucose and insulin, hyperkalemia, hypokalemia, 
hypercalcemia, and alcohol and cocaine toxicity4. A comprehensive list of medications to be 
avoided by Brugada syndrome patients can be found at www.brugadadrugs.org. This website is 
maintained by the University of Amsterdam Academic Medical Center, Department of 
Cardiology, and is updated regularly58
2.7 PSYCHOSOCIAL CONSIDERATIONS  
.   
There are limited studies that focus specifically on psychosocial aspects of Brugada syndrome. 
Many papers elude to decreased quality of life, anxiety, and depression in this patient population 
but have focused on other issues such as disease prevalence and ICD complications21,47,49,50. 
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There have been studies focused on quality of life and other psychosocial implications of 
inherited heart disease such as Long QT syndrome and Hypertrophic Cardiomyopathy and the 
results of these studies can be used as a point of reference to draw correlations to Brugada 
syndrome patients59–62
2.7.1 Disease Burden  
.  
Brugada syndrome is diagnosed at an average age of 40 years old and is more likely to be 
diagnosed in a man than in a woman. At-risk family members can be identified based on ECG 
analysis, provocative drug testing or genetic testing if there is a known family mutation.  Patients 
identified as having Brugada syndrome face a risk of arrhythmic events of up to 4.1% per year22
Patients with Long QT and Hypertrophic cardiomyopathy also face a significant risk of 
arrhythmic events and sudden cardiac death.  These patients often present for genetic counseling 
services with high levels of general anxiety. A study by Hamang et al. found that approximately 
25% of the patients in their study had clinical anxiety symptoms
. 
An arrhythmic event can include syncope and sudden cardiac death.  
60. This anxiety tends to be heart 
focused and can manifest as cardio-protective avoidance, heart-focused attention and fear of 
sudden cardiac death and heart sensations. Anxiety tends to be increased in these inherited heart 
conditions independent of demographic covariates such as age and gender as well as clinical 
variables such as a recent sudden cardiac death in the family60
This same research group conducted a one year follow up on their patient population and 
found continued evidence to support their claims
.  
61. In addition, they found that heart-focused 
anxiety was higher in patients with a clinical diagnosis of Long QT syndrome or Hypertrophic 
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Cardiomyopathy as compared to patients at genetic risk for these conditions61. Hamang et al. 
hypothesized that the reason for this increased anxiety may be due to the fact that these patients 
live with the genetic risk of a life-threatening disorder and the uncertainty regarding cardiac 
symptoms60
A study by Andersen et al. examined psychosocial aspects of living with Long QT 
syndrome including their daily life challenges and coping strategies
. The same set of criteria applies to Brugada syndrome and it is reasonable to 
anticipate the same concerns in that patient population.  
59
Another theme identified by Andersen et al.  was that fear of something happening to 
their children or grandchildren is often the largest concern patients with Long QT syndrome 
experience
. Sources of worry and 
anxiety identified in this study were unresolved emotions and worry on behalf of family 
members. In agreement with Hamang et al. this study also identified uncertainty about their 
condition and cardiac symptoms as sources of anxiety. Another theme identified by Andersen et 
al. was a sense of loneliness and isolation caused by having a rare condition. Few people in the 
general population are familiar with Long QT syndrome and as a result those with the condition 
felt that they had no close friends who could understand their perspective. This sense of isolation 
is common in other rare genetic conditions as well and Brugada patients may experience the 
same sentiment. Referral to a support group or online discussion forum may be of benefit to 
these patients to allow them to communicate with those who also have the condition.   
59. These participants favored early genetic testing and informing their children about 
their genetic status and risk for arrhythmic events and felt that this information would not induce 
unnecessary anxiety or worry for their children. A study by Smets et al. investigated the potential 
negative impact of informing children about their genetic risk status62. The results of their study 
showed that there was no difference in quality of life of carrier children as compared to a 
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representative sample of peers. They offered some caution as these results may be reassuring to 
those who express concern for informing children about their risk status yet it is possible that 
some may still experience problems and proper counseling and attention should be given to these 
patients.   
Patients with inherited cardiovascular disease are at risk for depression. In the Long QT 
symptomatic patient population, depression has been associated with arrhythmic events63. 
Interestingly, the study by Hintsa et al. did not show a relationship between asymptomatic 
carriers of a disease causing mutation and depression63. General cardiovascular research has 
identified an association between depression and increased probability of various cardiac events 
such as VT and VF64. There may be a connection between altered autonomic nervous system 
function and arrhythmias. This phenomenon may also apply to Brugada syndrome patients and 
medical professionals should take care to identify and assist those patients with signs of anxiety 
and depression. A study by Daoulah et al. that focused on assessing outcome after ICD 
placement in Brugada patients documented that five of their patients were diagnosed with 
depression50
2.7.2 Genetic Testing  
.  
Genetic testing for Brugada syndrome only identifies a disease causing mutation in 30% of 
symptomatic individuals. The remaining 70% still have the clinical diagnosis but have no genetic 
explanation for the condition. In addition, if a mutation is not identified then it becomes more 
difficult to assess family members and determine who is and is not at risk. Research has shown 
that in families where a mutation is already known, patients coming in for genetic testing have a 
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lower level of heart-focused attention and monitoring of cardiac activity than patients who are 
uncertain whether genetic testing has been performed in the family61. Medical professionals 
performing genetic testing should bear in mind that genetic testing is both an individual and a 
family affair43
Many parents with inherited cardiovascular disease express concern for their children’s 
well being
.  
61. In other genetic conditions, parents have experienced guilt related to having passed 
on a disease causing mutation to their children65–67
2.7.3 Implications of an ICD  
. Brugada syndrome is inherited in an 
autosomal dominant manner and children of an affected parent have a 50% chance of inheriting 
the disease causing allele. Strategies for dealing with guilt in this type of situation revolve around 
effective communication that there is nothing that the parent could have done or not done to 
prevent this from happening. In fact, genetic testing can help alleviate anxiety as those who test 
negative for the family mutation are not at risk for arrhythmic events.  
There have been several research studies that have focused on the psychosocial implications of 
having an ICD8,68–71. In Brugada syndrome, an ICD is recommended for all patients with a past 
history of aborted sudden cardiac death or syncope. For asymptomatic patients, the 
recommendations are less clear as more research is needed for proper risk stratification. This 
creates a dilemma for the asymptomatic patient and the physician. To quote Brugada et al., 
current methods “condemn patients to an individual approach based more on the personal 
experience of the treating physicians with other Brugada syndrome patients and the fear of 
dramatic events…This might lead to unnecessary overtreatment with devices.47”  
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Regardless of risk stratification, the final decision on whether or not to place an ICD rests 
on the patient. Motivators to accept an ICD include awareness of sudden cardiac death risks and 
the physician’s recommendations68.  Factors such as trust in the physician, social influences, and 
health state influence the decision making process the most68. Most patients begin their decision 
making process after a health-related “trigger”. For Brugada patients, this could be either an 
aborted sudden cardiac death or syncope. In asymptomatic patients, the trigger could be a history 
of sudden cardiac death in a family member or palpitations leading to a fear of sudden cardiac 
death. The decision process can take a few moments for some patients and up to two years in 
others68
To assist patients with their decision making process, it is important to discuss all the 
benefits and limitations of the device. In particular to Brugada syndrome, the limitations of the 
device and complications should be addressed. As described previously in this document, there is 
concern for a high rate of inappropriate shocks in Brugada patients. The rate of inappropriate 
shocks is often greater than appropriate therapy and the annual risk of inappropriate shocks has 
been reported to be as high as 18%  per year
.   
53. An incidental finding by Daoulah et al. was 
depression in Brugada patients with an ICD. Two of their patients suffered from insomnia due to 
phobia after receiving inappropriate shocks50
It is rare for Brugada syndrome to affect children, but there have been reports of 
adolescents being affected and having an ICD. Less than 1% of ICD patients are under 21 years 
of age and this population may have a unique set of psychosocial considerations
. In addition, Brugada patients often receive an ICD 
at a younger age compared to other patients with an ICD. This results in higher rates of 
complications such as device change out surgery and lead malfunction.  
69.  There can be 
negative stigma associated with body image, inability to do some activities, and increased 
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frequency of doctors’ appointments. An interesting theme that emerged from the study by 
Rahman et al. was that parents often viewed their children as being “normal” but the adolescents 
described themselves as being “not normal” or “different”69. One adolescent with Brugada 
syndrome in the study described his life after placement of the device as follows: “…that I am 
limited more um [pause] that I have to be careful what I do, that I’m not as able as I was 
beforehand but am a lot more aware now. 69”  
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3.0  AIMS OF THE STUDY  
3.1 SPECIFIC AIM 1: ASSESSMENT OF BRUGADA MANAGEMENT 
To assess the factors that determine management decisions for Brugada syndrome patients.  
3.2 SPECIFIC AIM 2: ASSESSMENT OF QUALITY OF LIFE  
To determine how Brugada syndrome patient management impacts quality of life and if any 
differences exist between symptomatic, asymptomatic, those with an ICD and those without an 
ICD. Three different hypotheses were generated:  
1. Is there a difference in quality of life between those with a genetic mutation that causes 
Brugada syndrome and those without one?  
2. In individuals who have a genetic mutation that causes Brugada syndrome, is there a 
difference in quality of life between those who are symptomatic and those who 
asymptomatic?  
3. In symptomatic individuals with a genetic mutation that causes Brugada syndrome, is 
there a difference in quality of life between those who have an ICD and those who do 
not?  
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4.0  MATERIALS AND METHODS  
4.1 STUDY POPULATION 
The Institutional Review Board at the University of Pittsburgh approved all human studies. The 
study population chosen for this investigation is a large multigenerational family with Brugada 
syndrome. The full history of this family has been described previously in a research study by 
Weiss et al. 72
When this family was first enrolled in the research study, the underlying genetic etiology 
of Brugada syndrome was not known. Family members were considered affected or not based on 
the findings of their ECGs. Brugada syndrome was diagnosed in any family member who had at 
least a single ECG with a RBBB pattern (RSR’ in leads V1 or V2) and greater than 1 mm of J-
point elevation and ST elevation (measured 80 ms after the J-point) in the right precordial leads 
. To summarize, the proband was referred to the University of Pittsburgh Medical 
Center after a syncopal event in 1996. At-risk family members were enrolled in a research study 
to elucidate the genetic cause of Brugada syndrome in the family. All family members have a 
brief clinical history and a 12-lead ECG on file. Some members participated in additional cardiac 
testing which included 24-hour holter monitors, echocardiograms, procainamide drug testing, 
and cardiac MRIs. Serial ECGs have been obtained on most family members every 6 months to a 
year when possible.  
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V1 through V3. However, it is well established that due to reduced penetrance of Brugada 
syndrome not every person with the condition will have characteristic findings on ECG. 
 In 2007, the underlying genetic etiology was identified as an A280V mutation in 
GPD1L35
4.2 ASSESSMENT OF PATIENT ICD AND GENETIC STATUS 
. All family members were then tested to see if they carried the familial mutation or not, 
even those who were considered to be unaffected based on ECG findings. Genetic testing 
allowed the identification of at risk individuals as well as the ability to define those who were 
truly affected and unaffected.   
A questionnaire was created to assess patient demographic information and medical management 
decisions. The document can be found in Appendix B. The questionnaire was divided into four 
sections.  
4.2.1 Part I: General Information  
This section was designed to better understand the participant’s demographics. The questions 
focused on age, gender, ethnicity, education, marital status, occupation, and living arrangements.  
4.2.2 Part II: Diagnosis History  
The purpose of this section was to assess the participant’s understanding of his or her personal 
diagnosis and family history. The questions dealt with whether or not the participant had a 
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diagnosis of Brugada syndrome, genetic status, and clinical symptoms. Participants were also 
asked to identify other family members diagnosed with Brugada syndrome.  
4.2.3 Part III: Device History  
The third section of the questionnaire focused on whether or not the participant had an ICD. It 
also provided an opportunity for the participants to share their personal reasons as to why they 
did or did not choose an ICD.   
4.2.4 Part IV: Follow Up History  
The last portion of the questionnaire was designed to assess how compliant the participants were 
in following with a cardiologist and/or an electrophysiologist based on ICD status.  
4.3 ASSESSMENT OF QUALITY OF LIFE 
The Medical Outcome Study 36-item short-form health survey version 2.0 (SF-36v2) was used 
to assess each participants quality of life73. The SF-36v2 is a validated instrument for assessing 
quality of life that utilizes eight health domains: physical functioning, role limitation caused by 
physical problems, bodily pain, general health perception, vitality, social functioning, role 
limitation caused by emotional problems and mental health. The eight scales are scored from 0 to 
100. The survey uses norm-based scoring which allows comparisons among different 
populations. The SF-36v2 also provides two summary measures, physical component summary 
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(PCS) and mental component summary (MCS), to further characterize quality of life. The figure 
below qualitatively depicts how the eight different scales are combined to form the PCS and the 
MCS.  
 
4.4 DATA COLLECTION 
For this study, all participants were contacted in person. Informed consent was obtained and each 
participant filled out a Long Term Follow Up Questionnaire (Appendix B) and the Medical 
Outcome Study 36-item short-form health survey version 2.0 (SF-36v2). The questionnaires 
Figure 3: The SF36v2 Scales and Their Relationship to the Component Summaries 
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were stored with the participants’ original research files containing their medical histories and 
cardiac testing information.  
4.5 STATISTICAL ANALYSIS 
The SF-36v2 questionnaire was analyzed using the SF Health Outcomes™ Scoring 
Software (Quality Metric Inc., Lincoln, USA), as already described. Additional statistical tests 
were used to evaluate the significance of the results including two-sample t test and regression 
analysis.  
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5.0  RESULTS 
5.1 POPULATION DEMOGRAPHICS 
As described in Materials and Methods, the family approached for this research study is a large, 
multigenerational family. Over two hundred family members are enrolled in the larger research 
study that this thesis project is a part of. Clinical follow-up of the family has been continued for 
the past fifteen years with annual visits for updated ECGS and status reports. The family is of 
Italian ethnicity with no known consanguinity. There are no other known genetic conditions in 
this family. A pedigree of the entire family is presented below (Figure 4) 35.  
Figure 4: Pedigree of the Family in this Study 
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Seventeen total participants were enrolled in the research study. One family member was 
approached and declined to participate in the study. The mean age of the study population was 
57 years old with a range from 36 to 89 years old. Twelve of the participants were male (71%) 
and five were female (29%). Ten of the participants had the familial A280V GPD1L mutation 
(59%). Of those with the GPD1L mutation, seven (70%) were affected and had an identifiable 
Brugada ECG pattern with or without clinical symptoms. The remaining three participants with a 
mutation have had no clinical symptoms or identifiable Brugada ECG pattern to date. Table 7 
summarizes the general characteristics of this study population.  
Table 7: General Characteristics of Study Population 
 
 
 
 
 
 
 
ID Age Gender Genetic Status* Affected ICD † 
1 (proband) 70 M A280V Yes Yes 
2 43 M A280V Yes No 
3 63 M WT Yes No 
4 54 F A280V No No 
5 36 M A280V Yes Plan on getting one 
6 45 M A280V Yes Yes 
7 39 M A280V No No 
8 46 F A280V No No 
9 89 M A280V Yes No 
10 72 M A280V Yes No 
11 50 M WT No No, had one in the past 
12 60 M WT No No 
13 63 M WT No No 
14 75 M A280V Yes Yes 
15 85 F WT No No 
16 38 F WT No No 
17 43 F WT No No 
*GPD1L 
† Past history of syncope, palpitations, or dizziness/lightheadedness and/or Brugada ECG Pattern 
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Seven of the participants with the familial mutation have experienced clinical symptoms 
or have a documented Brugada ECG pattern (Table 8). None of the participants have 
experienced an aborted sudden cardiac death, and there is no history of sudden cardiac death in 
this family overall. All seven of these participants have an identifiable Brugada ECG pattern. 
Three have a history of syncope and have received an ICD due to this clinical symptom. Five 
report having experienced palpitations as well as felling dizzy/lightheaded.  
Table 8: Clinical Symptoms of Participants with the GPD1L Mutation 
Participant Clinical Symptoms 
1 (proband) Brugada ECG Phenotype, syncope, dizzy/lightheaded, palpitations 
2 Brugada ECG Phenotype 
5 Brugada ECG Phenotype, palpitations, dizzy/lightheaded 
6 Brugada ECG Phenotype, syncope, dizzy/lightheaded, palpitations 
9 Brugada ECG Phenotype 
10 Brugada ECG Phenotype, palpitations, dizzy/lightheaded 
14 Brugada ECG Phenotype, syncope, dizzy/lightheaded, palpitations 
 
Three of the family members with a mutation and clinical symptoms have an ICD, one of 
which is the proband (Table 9). The average age of ICD placement was 56 years old with a range 
from 39-75. Two of the individuals with an ICD have received shocks from their device. 
Participant 1 (proband) has had two episodes of polymorphic ventricular tachycardia that were 
terminated by appropriate ICD shocks. Participant 6 has received four shocks from the device; 
all four were consistent with inappropriate shocks due to a low monitoring threshold. Although 
participant 14 has not received a shock, there is a documented 20-beat episode of ventricular 
flutter that self-terminated and did not require a shock from the ICD.  
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Table 9: Characteristics of Participants with ICDs 
Participant Current Age Gender 
Age at Device 
Placement 
Shocked Number 
1 70 M 56 Yes 2 appropriate 
6 45 M 39 Yes 4 inappropriate 
14 75 M 75 No None 
 
 One family member, participant 11, had an ICD in the past but has since had it removed. 
Brugada syndrome was diagnosed in this family in 1997; however, the genetics underlying the 
condition in were not discovered until 2007. Until the mutation in GPD1L was discovered, the 
only means of identifying at risk family members were an ECG and drug testing. Based on 
nonspecific ECGs and a history of syncope, participant 11 was believed to have Brugada 
syndrome and be at risk for arrhythmias. He chose to have an ICD placed to protect against fatal 
arrhythmias. However, once the familial mutation was discovered and the family revisited, it was 
discovered that participant 11 did not have the A280V GPD1L mutation and was thus not at risk 
for arrhythmias due to Brugada syndrome. As a consequence, this family member chose to have 
the ICD removed as it was no longer necessary.  
 Participant 5 reported that he plans on getting an ICD in the future. In addition to the 
Brugada ECG phenotype, he has experienced palpitations and felt dizzy/lightheaded before but 
denies syncope.  
 Only two patients are regularly following with a local cardiologist and both are clinically 
affected and have ICDs. None of the clinically affected, gene positive individuals without a 
mutation are currently seeing a local cardiologist. Additionally, none of the participants who 
have the familial mutation but no clinical symptoms see a local cardiologist.   
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5.2 REASONS FOR CHOOSING AN ICD 
The Long Term Follow Up Questionnaire was designed to evaluate the reasons and motivations 
Brugada syndrome patients choose or decline an ICD. In this study, three individuals with the 
A280V GPD1L had an ICD. An open-ended question on the questionnaire gave the participants 
an opportunity to share the reason why they choose to have an ICD placed. Their responses are 
listed below:  
• “I needed it.” –Participant 1, proband 
• “No choice.” –Participant 6 
• “To help my children to be to know what to look for with their heart. Get 
regular check up, also because of family history.” –Participant 14   
Participant 5 reported that he plans on getting an ICD in the future. His response to the 
open-ended question of why he will get one in the future is as follows:  
• “If symptoms should appear at some point, then I don’t have much of a choice.”  
–Participant 5 
A follow up question asked why the participant did not have an ICD currently to which 
participant 5 responded:  
• “I do not need one yet.” –Participant 5  
As previously mentioned, participant 11 was incorrectly identified as having Brugada 
syndrome and had an ICD in the past. An open-ended question was designed to ascertain the 
reason for choosing to have an ICD removed. His response was:  
• “Do not have Brugada syndrome.” –Participant 11 
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Although not marked on the questionnaire as planning to get an ICD in the future, 
participant 2 answered the opened ended question regarding why he will choose to get an ICD in 
the future. He wrote:  
• “If I ever need one. For the kids for my wife – for longevity.” –Participant 2 
He also answered the follow up question about why he chose not to have an ICD 
currently with: 
• “I do not need one yet.” –Participant 2  
5.3 RESPONSES TO THE SF-36V2 HEALTH SURVEY  
The participants were divided into four separate groups to facilitate data analysis (Table 10). 
Group 1 consists of the two participants who carry the GPD1L mutation but have no clinical 
symptoms and is referred to as the “Gene Positive Asymptomatic”. Participant 8 was excluded 
from data analysis as she was recently diagnosed with Crohn’s disease and her responses to the 
SF36v2 Health Survey were reflective of that health condition and not Brugada syndrome. Group 
2 consists of the four participants who carry the GPD1L mutation and are clinically affected but 
do not have an ICD and is referred to as “Gene Positive Symptomatic”. Group 3 consists of the 
three participants who carry the GPD1L mutation, are clinically affected, and have an ICD. 
Group 3 is referred to as “Gene Positive Symptomatic ICD.” The last group, Group 4, consists of 
the seven participants who do not carry the family mutation in GPD1L and is referred to as 
“Gene Negative”.  
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Table 10: Group Classifications of Participants 
Group Size (n) Participants Age Gender Symptoms ICD 
Group 1 
Gene Positive 
Asymptomatic 
2 
4 54 F 
None No 
7 39 M 
 
Group 2 
Gene Positive 
Symptomatic 
4 
2 43 M 
Brugada ECG Phenotype, 
palpitations, dizzy/lightheaded 
No 
5 36 M 
9 89 M 
10 72 M 
 
Group 3 
Gene Positive 
Symptomatic ICD 
3 
1 (proband) 70 M Brugada ECG Phenotype, 
syncope, dizzy/lightheaded, 
palpitations 
Yes 6 45 M 
14 75 M 
 
Group 4 
Gene Negative 
7 
3 63 M 
None No 
11 50 M 
12 60 M 
13 63 M 
15 85 F 
16 38 F 
17 43 F 
5.3.1 General Responses of All Groups within the Study Population  
The SF36v2 scores all eight scales from 0-100. These eight scales are physical functioning (PF), 
role limitation caused by physical problems (RP), bodily pain (BP), general health perception 
(GH), vitality (VT), social functioning (SF), role limitation caused by emotional problems (RE) 
and mental health (MH). The software package normalizes the raw scores (0-100) to a mean of 
50 and a standard deviation of 10 referred to as norm based scoring (NBS). In addition, US 
general population norms from 1998 are built into the algorithm. Thus the NBS allows accurate 
comparison between the eight scales and is already compared with general population data. For 
this reason, the NBS values were used for data analysis. There were no missing responses on any 
of the surveys.   
 Overall, the average for each scale and summary component fell within one standard 
deviation of the mean. The NBS for each group and the average NBS for the groups are 
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compared in Table 11. The average score for the PCS in Group 1 was 44.64; Group 2 was 50.86; 
Group 3 was 57.91; and Group 4 was 48.41. The average MCS score for each group was as 
follows: 57.31 for Group 1, 60.23 for Group 2, 50.13 for Group 3, and 55.34 for Group 4.  The 
lowest scale group average was found in the BP scale in Group 1 (39.30). The highest scale 
group average was observed in the VT mean for Group 2.  
Table 11: SF36v2 Norm Based Scores for All Participants 
 Participant PF RP BP GH VT SF RE MH PCS MCS 
G
ro
up
 1
   
   
   
  
(n
 =
 2
) 4 46.51 56.85 41.41 48.17 64.58 56.85 55.88 61.27 44.49 64.12 
7 52.82 56.85 37.18 45.78 45.85 56.85 55.88 44.38 48.42 50.50 
Group Average 49.67 56.85 39.30 46.98 55.22 56.85 55.88 52.83 46.46 57.31 
G
ro
up
 2
   
   
   
   
   
   
   
   
   
(n
 =
 4
) 
2 57.03 56.85 55.36 44.83 67.70 56.85 55.88 61.27 52.64 61.13 
5 57.03 56.85 50.29 52.93 55.21 56.85 55.88 58.46 53.31 57.19 
9 40.20 47.06 46.06 55.32 61.46 51.40 48.10 61.27 43.08 60.64 
10 57.03 56.85 51.13 60.08 64.58 56.85 55.88 64.09 54.39 61.94 
Group Average 52.82 54.40 50.71 53.29 62.24 55.49 53.94 61.27 50.86 60.23 
G
ro
up
 3
   
   
   
   
   
   
   
   
 
(n
 =
 3
) 
1 (proband) 57.03 56.85 55.36 43.40 55.21 56.85 32.56 58.46 57.02 46.72 
6 57.03 56.85 50.29 60.08 48.97 56.85 55.88 52.82 56.16 52.87 
14 57.03 56.85 62.12 50.55 67.70 56.85 55.88 41.56 60.56 50.81 
Group Average 57.03 56.85 55.92 51.34 57.29 56.85 48.11 50.95 57.91 50.13 
G
ro
up
 4
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
(n
 =
 7
) 
3 50.72 44.61 41.41 52.93 61.46 56.85 55.88 55.64 44.32 61.12 
11 57.03 56.85 62.12 63.90 70.82 56.85 55.88 52.82 61.50 56.81 
12 57.03 56.85 55.36 57.70 58.33 56.85 55.88 50.01 58.07 53.25 
13 46.51 51.96 37.18 57.70 61.46 56.85 55.88 61.27 43.72 64.25 
15 33.88 37.26 32.96 30.53 48.97 40.49 44.22 50.01 29.57 51.94 
16 44.40 47.06 46.06 41.02 45.85 45.94 48.10 50.01 43.37 49.29 
17 57.03 56.85 55.36 50.55 64.58 56.85 55.88 41.56 58.33 50.73 
Group Average 49.51 50.21 47.21 50.62 58.78 52.95 53.10 51.62 48.41 55.34 
5.3.1.1 Adjustment for Age – PCS  
The data was first evaluated to see if there was any affect of age on the physical scales and 
component summary. Regression analysis identified the following trends (Figure 5). When 
looking at the PCS, there was a trend toward lower physical quality of life and increasing age 
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although it was not statistically significant (p-value = 0.259). When looking at each physical 
scale individually, the same trend was observed for all four. None of these regression analyses 
were statistically significant either. The PF and RP scales showed the strongest correlation with 
age with a p-value of 0.085 and 0.079 respectively.  
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Figure 5: PCS and Related Summary Measures Correlation with Age 
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5.3.1.2 Adjustment for Age – MCS  
 
Figure 6: MCS and Related Summary Measures Correlation with Age 
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Regression analysis was also used to evaluate age variation for the mental health scales and 
summary component (Figure 6). The mental quality of life tended to increase with older age but 
was not statistically significant (p-value = 0.595). Each of the four scales that comprise the MCS 
was evaluated separately for age variation. VT and MH showed a weak trend toward increased 
quality of life with older age, however, it was not statistically significant (p-value 0.423 and 
0.432 respectively). Of interest, SF and RE showed a trend toward decreased mental quality of 
life and older age. These trends were also not statistically significant (SF p-value = 0.267; RE p-
value = 0.118).  
5.3.1.3 Adjustment for Gender – PCS   
Two-sample t test for unequal variance was used to evaluate the data for variation according to 
gender. There were twelve total males in this study and four females. For the PCS, males had a 
higher average score than females (Figure 7). The average score for the males was 52.77 and the 
average score for the females was 43.94. This difference was not statistically significant (p-value 
0.226).  
 
 
 
 
 
 
 
 
Figure 7: PCS Variation with Gender 
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Each of the four physical scales was also analyzed for variation with gender. Similarly to 
PCS, all four scales had higher averages in the males than females (Table 12). These differences 
were not statistically significant.  
Table 12: Four Physical Scales Variation with Gender 
 
n PF RP BP GH 
Males 12 53.87 54.61 50.32 53.77 
Females 4 45.46 49.51 43.95 42.57 
p-value  0.168 0.370 0.281 0.083 
5.3.1.4 Adjustment for Gender – MCS  
MCS was also analyzed using a two-sample t test for unequal variance to evaluate gender 
variation (Figure 8). The MCS average in males was 56.44 and in females 54.02. The mental 
health quality of life was higher in the males similar to the physical quality of life; however this 
difference was also not statistically significant (p-value = 0.556).  
  
 
 
 
 
 
 
  
Figure 8: MCS Variation with Gender 
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 Each of the four mental scales was also analyzed for variation with gender (Table 13). In 
general, these scores were all higher in males than in females although none reached statistical 
significance.  
Table 13: Four Mental Scales Variation with Gender 
 n VT SF RE MH 
Males 12 59.90 56.40 53.29 55.17 
Females 4 56.00 50.03 51.02 50.71 
p-value  0.514 0.220 0.544 0.370 
5.3.2 Hypothesis 1: Gene Negative vs. Gene Positive  
To assess the difference in quality of life between participants with A280V GPD1L mutation 
(Gene Positive) and those without it (Gene Negative), a two-sample t test for unequal variance 
was performed (Table 14). Overall, there was no significant difference in any of the eight scales 
between those with and without the mutation.  
Table 14: SF26v2 Mean Responses by Genetic Status 
 
n PF RP BP GH VT SF RE MH 
Gene Negative 
Group 4 
7 49.51 50.21 47.21 50.62 58.78 52.95 53.10 51.62 
Gene Positive 
Groups 1-3 
9 53.52 55.76 49.91 51.24 59.03 56.24 52.42 55.95 
p-value  0.323 0.108 0.584 0.900 0.955 0.257 0.836 0.238 
 
 The summary component scores, PCS and MCS, were also evaluated to see if any 
differences existed by genetic status (Figure 9). The scores were higher for participants who had 
the mutation for both PCS and MCS. However, neither one had a significant difference.   
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p-value = 0.442 p-value = 0.772 
 
 
5.3.3 Hypothesis 2: Asymptomatic vs. Symptomatic  
The data was analyzed with a two-sample t test for unequal variance to assess differences in 
quality of life in participants who had the genetic mutation and either had symptoms or did not 
(Group 1 versus Group 2-3). In general, the physical scales (PF, BP, and GH) were on average 
higher in the symptomatic group (Table 15). The average for BP in the asymptomatic group was 
39.30 and the average in the symptomatic group was 52.94. This difference reached statistical 
significance with a p-value of 0.017. However, there was a small number of participants in 
Group 1 (n=2).  
In the mental scales, there was no general trend observed as some averages were higher 
in symptomatic participants (VT and MH) and others were lower (SF and RE). None of the 
mental scale differences were significant (p-values 0.231 – 0.718).  
 
 
Figure 9: PCS and MCS Differences by Genetic Status 
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Table 15: SF26v2 Mean Responses by Brugada Symptom Status 
 
n PF RP BP GH VT SF RE MH 
Asymptomatic  
 Group 1 
2 49.67 56.85 39.30 46.98 55.22 56.85 55.88 52.83 
Symptomatic  
 Groups 2-3 
7 54.63 55.45 52.94 52.46 60.12 56.07 51.44 56.85 
p-value  0.321 0.356 0.017 0.091 0.693 0.356 0.231 0.718 
 
 The MCS and PCS summaries were analyzed as well (Figure 10). The PCS mean was 
higher in the symptomatic group (53.88 versus 46.46). This difference was almost significant 
with a p-value of 0.065. The differences in MCS were reversed as compared to PCS scores. The 
mean was higher in the asymptomatic group (57.31 versus 55.90), yet this difference did not 
reach statistical significance (p-value = 0.872).   
 
5.3.4 Hypothesis 3: No ICD vs. ICD  
The final data analysis was a two-sample t test for unequal variance to evaluate differences 
between symptomatic patients with and without a device (Group 2 versus Group 3). All 
Figure 10: PCS and MCS Differences by Brugada Symptom Status 
49 
 
participants in these two groups were male. When comparing the eight scales, none of the 
differences were significant. PF, RP, and BP were higher in those with and ICD whereas VT, 
RE, and MH were lower (Table 16).  
Table 16: SF26v2 Mean Responses by ICD Status 
 
n PF RP BP GH VT SF RE MH 
No ICD  
Group 2 
4 52.82 54.40 50.71 53.29 62.24 55.49 53.94 61.27 
ICD              
Group 3 
3 57.03 56.85 55.92 51.34 57.29 56.85 48.11 50.95 
p-value  0.391 0.391 0.270 0.755 0.479 0.391 0.535 0.168 
 
PCS was higher in those with an ICD, similar to the results found with the physical scales 
PF, RP, and BP (Figure 11). This difference was almost significant with a p-value of 0.069. The 
difference between MCS means was significant with a p-value of 0.013. The mean MCS in ICD 
participants was 50.13 as compared to 60.23 in the symptomatic patients without an ICD.   
 
Figure 11: PCS and MCS Differences by ICD Status 
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6.0  DISCUSSION 
6.1 SPECIFIC AIM 1 
The purpose of the Long Term Follow Up Questionnaire was to evaluate the reasons a patient 
with Brugada syndrome chooses or declines an ICD. In this sample, three participants chose to 
get an ICD and one reported planning to get one. All four of these participants answered an 
open-ended question about the reason they made their decision. In addition, one participant does 
not plan on getting an ICD in the future but still answered the question. The responses are listed 
in the Results section of this document and described again below.  
When evaluating the responses, two themes emerged. The first theme identified was ICD 
decision making due to a sense of inevitability or necessity. Three of the responses fell into this 
category. The first two were from participants who had an ICD already and the last was from the 
participant who plans to get an ICD in the future: 
• “I needed it.”- Participant 1 (proband)  
• “No choice.” – Participant 6 
• “If symptoms should appear at some point then I don’t have much of a choice.”   
–Participant  5 
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These responses indicate that the patients’ decision making to accept an ICD was more of 
a necessity and not an option. These findings are similar to a study by Agard et al. that looked at 
the decision making process regarding ICD therapy in patients with heart failure and prior 
history of arrhythmias74
The second theme that emerged was the decision to choose an ICD for family or spouse 
benefit. Two responses fell into this category, one from a participant with an ICD and one from a 
participant who does not plan on getting an ICD in the near future but answered the question 
regardless: 
. In their study, patients who survived a cardiac arrest felt that the offer 
of an ICD could not be refused. This decision reflects a belief that doctors know what is best for 
the patient and a trust in their decision for the patient. It also reflects a belief that life is valuable 
and that any precautions should be taken to preserve and prolong it.  
• “To help my children to be to know what to look for with their heart. Get regular 
check up, also because of family history.” –Participant 14 
• “If I ever need one. For the kids for my wife – for longevity.” –Participant 2  
These participants may have also felt a sense of necessity and/or inevitability but they did 
not report it in their responses. Instead, their responses highlight that the main reason for 
choosing an ICD was or would be for the benefit and reassurance of a spouse or family member. 
Brugada syndrome carries a risk for sudden cardiac death that can be difficult for both the patient 
and their family to come to terms with and accept. An ICD can intervene should a serious 
arrhythmia occur and prevent sudden death. In these patients, the ability to provide a sense of 
relief and safety to their spouses and family was reason enough to choose an ICD.  
Based on these responses, medical professionals working with Brugada syndrome 
patients may find it useful to take time to carefully explain the benefits, risks, and limitations of 
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an ICD to those considering one. Although it is difficult to estimate the exact risk of arrhythmia 
and sudden cardiac death in this patient population, there have been several studies that estimate 
the risk and the differences observed between these groups can be presented to the patients as a 
range of risks. Hopefully in the future more research will become available to clarify the risks 
and provide more accurate information to aid patients in their decision-making process.  
6.2 SPECIFIC AIM 2 
The SF36v2 health survey was used to evaluate quality of life in this patient sample. The NBS 
values were used for comparison as these values have all been scored to have the same mean 
(50) and standard deviation (10). The algorithm also incorporates general population norms for 
the general United States Population circa 1998. An individual score below 45 or a group mean 
below 47 can be interpreted as being below the average range for the general population.  
Only 16 participants were used for the data analysis; Participant 8 was excluded due to a 
recent diagnosis of Crohn’s disease. When evaluating the responses overall for each participant, 
eleven participants had scores lower than 45 in at least one scale. The most common scale with a 
score lower than 45 was bodily pain (BP) and general health (GH). These lower scores are 
reflected in the score for PCS, which was below 45 in six of the participants. None of the MCS 
scores were below 45, indicating no differences in mental quality of life as compared to the 
general population.  
The majority of the group means were above 47, however, there were three scales that 
were below the cut-off of 47 and all were in Group 1. The BP, GH and PCS means were 39.30, 
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46.98, and 46.46 respectively. As BP and GH are used in the calculation of PCS, it follows that a 
lower quality of life in those physical scales would lead to a lower physical component summary.  
In this data set, a trend was observed that as age increased, the physical quality of life 
decreased. Even though the correlation was not significant, this overall trend has been observed 
and reported on for the SF-36v2. The MCS component for this sample showed a positive 
correlation between increasing age and increased quality of life. However, when examining each 
of the four scales that comprise MCS (VT, SF, RE, and MH), the trend varied. These trends also 
were comparable to reported age variation within these scales. Thus overall, the variation with 
respect to age matched what is typically seen in the US population.  
The data set was also analyzed for variation with gender. Across the board, the males’ 
responses were higher. None of the scales or component summaries reached statistical 
significance. However, like age variation, the SF36v2 responses tend to be higher in males and 
lower in females. In short, gender variation observed in this population also correlates with the 
trend in the US population.  
The first hypothesis sought to identify any differences in quality of life between family 
members with the A280V GPD1L mutation and those without it. There were no statistical 
differences in quality of life between the two groups when comparing the summary scores and 
the eight individual scales. In general, the scores were higher in the Gene Positive group. This 
data indicates that those with the genetic diagnosis of Brugada syndrome in this family in general 
have a good quality of life.  
The second hypothesis was to determine if any differences due to symptom status existed 
in those with the genetic diagnosis of Brugada syndrome. The PCS was higher in those with 
symptoms while their MCS scores were lower. A similar pattern was seen in the eight scales 
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with those contributing to PCS being higher and those contributing to MCS being lower. Only 
the difference between BP scores reached statistical significance; the rest had p-values greater 
than 0.05. In summary, symptomatic Brugada syndrome patients have a comparable quality of 
life to asymptomatic patients with a tendency toward better physical quality of life.  
The third and final hypothesis was to evaluate differences in quality of life due to ICD 
status in symptomatic Brugada patients. None of the eight scales were significant on their own. 
PCS was higher in those with and ICD with a p-value of 0.069. The MCS score, in contrast, was 
lower in those with an ICD and the p-value was 0.013. This data indicates that Brugada patients 
with an ICD in this family experience a higher physical quality of life but a lower mental quality 
of life.  
With respects to physical quality of life, those with an ICD may experience less physical 
limitations as they feel dependent and protected by their ICD whereas those without an ICD may 
limit their physical activities due to fear of an arrhythmic event. Even though a trend was 
noticed, the means for both groups were above 50, the US population mean, and indicate that 
both have a good quality of life. An explanation of the difference in MCS due to ICD status 
could be explained by a fear of ICD shock leading to anxiety as has been reported in other 
patient populations with these devices.  
A study by Probst et al. also looked at the impact of ICD implantation on quality of life in 
Brugada patients9. In their study population, they did not identify any difference in responses to 
the SF36 (the first version the 36-item short from health survey) between Brugada patients with 
or without a device. However, they also implemented a questionnaire to the participants that 
showed 48% of Brugada patients felt that the diagnosis had a negative impact on their quality of 
life. 55% of participants with an ICD reported no difficulties with their physical activities, which 
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is comparable to this research with a high physical quality of life in those with an ICD. Sixty-two 
percent of the participants in the study by Probst et al. felt that having an ICD was detrimental to 
their social quality of life, citing difficulties with obtaining insurance and obstacles in their 
career. These same difficulties could be possible explanations for the lower mental component 
summary in ICD patients observed in this research study. 
In conclusion, Brugada syndrome patients in this family enjoy a good quality of life as 
compared to both the US population and family members without the condition. Symptomatic 
Brugada patients also experience a good quality of life; however, those with an ICD in this study 
had a lower mental quality of life. As discussed in relation to decision-making and ICD status 
earlier, medical professionals, especially genetic counselors, should bear this information in 
mind when discussing the option of ICD placement with these patients.  
6.3 LIMITATIONS AND FUTURE DIRECTIONS 
6.3.1 Limitations 
This study was conducted in a small sample (seventeen total participants but only sixteen used 
for data analysis). Gender and age distribution was not equal in the different sub-groups. It is 
possible that these may account for some of the differences observed in this study. All of the 
participants in this study were from the same multigenerational family. The differences in quality 
of life may be unique to this family and may not be reproducible in other populations. As all the 
participants came from a single family, there may be shared values, attitudes, perspectives, and 
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environmental factors that affect world-views regarding quality of life and medical treatment. 
Additional studies will confirm if the conclusions drawn from this family have universal 
applications.  
The SF36v2 was not specifically created for use in the Brugada syndrome patient 
population. Another survey may be able to better identify differences in quality of life in these 
patients.  
The way the Long Term Follow Up Questionnaire, Part II: Diagnosis History was worded 
failed to asses patient understanding of their genetic status. There was not an option for 
participants to choose “No” for diagnosis and still continue on to answer if they had participated 
in genetic testing. The information reported on from this questionnaire regarding genetic status 
was taken from their medical record. All other responses to the questionnaires were used directly 
as reported by the patient.  
6.3.2 Future Directions 
This study demonstrated that there is a difference in quality of life in Brugada syndrome patients 
with an ICD versus those who do not. Future research should be aimed at enrolling a larger 
sample size and focusing on Brugada patients with and without a known genetic mutation as well 
as those with or without an ICD. It would also be worthwhile either to continue this study in the 
same family and attempt to administer the SF36v2 to all family members with the condition and 
reassess the differences or to enroll other families and compare the quality of life between 
families to assess for differences in coping mechanisms.  
. 
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ADDENDUM 
 
CONSENT TO ACT AS A SUBJECT IN A CLINICAL STUDY 
 
TITLE: FAMILIAL STUDIES IN CARDIOVASCULAR DISEASE 
 
 
PRINCIPAL INVESTIGATOR 
Barry London, M.D., Ph.D. 
Associate Professor of Medicine 
1744 Biomedical Science Tower 
200 Lothrop Street 
Pittsburgh, PA 15213 
(412) 383-8750 
 
 
CO-INVESTIGATORS 
Sarah Richards Rebecca Gutmann, RN BSN 
Graduate Student Researcher Research Nurse Coordinator 
1704 BST, 200 Lothrop St. 1744.2 BST, 200 Lothrop St 
Pittsburgh, PA 15213  Pittsburgh PA 15213 
(412) 383-9761 (412) 383-7339 
 
 
SOURCE OF SUPPORT: National Institute of Health 
 
 
 
 
RESEARCH PURPOSE 
You or your child are currently a participant in a research study because you or a family 
member has a history of abnormal electrocardiograms (ECG’s) and sudden cardiac death. In your 
family, the cause of these events is due to an inherited heart condition called Brugada syndrome 
or Long Q T syndrome. Because you or your child have been diagnosed with one of these 
syndromes, we are asking you to complete two questionnaires about your  experiences and 
choices related to these syndromes as well as your overall health  and wellbeing. These 
questionnaires will take about 30 minutes total to complete, and contain questions about how you 
or your family m ember were diagnosed, treatment received ( if any), and current health status. 
We are asking 25 people who are enrolled in the main study to complete this questionnaire.  We 
hope to obtain a better understanding of the choices about implantable cardioverter defibrillators 
and overall health and wellbeing in families with Brugada syndrome or Long QT syndrome. 
 
POTENTIAL BENEFITS 
There are no direct benefits to you by taking part i n this research study.  By answering 
the que stions in these questionnaires you will he lp us identify information that we can provide 
that would help you to better unde rstand these syndromes. The information from the study may 
help educate other families with either Brugada syndrome or Long QT syndrome. 
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POTENTIAL RISKS 
The risks of completing the questionnaires  include potential discomfort answering 
personal questions and the possibility of a breach of confidentiality. Any information about you 
obtained f rom this research will be kept a s confidential a s possible. All records r elated to your 
involvement i n t his research study will be stored i n locked file cabinets i n t he Cardiovascular 
Institute of the University of Pittsburgh. Your identity on these records will be indicated by a 
code number rather than by your name and the information linking these case numbers with your 
identity will be kept separate f rom the research records. You will not be identified by name in 
any publication of  research results unless  you sign a  separate consent form giving  your 
permission (release). 
 
ALTERNATIVES 
This research study involves no medical therapy  or treatment.   The alternative to 
participating in this study is to not participate. 
 
 
 
 
VOLUNTARY CONSENT: 
All of the above has been explained to me by one of the Co-investigators in the research 
study and all of my current questions have been answered.  I understand that I am encouraged to 
ask questions about any aspect of this research study during the course of this study and that the 
researchers listed on the first page of this form will answer such future questions.  Any questions 
I have about m y rights as a research participant will be answered by the Human Subjects 
Protection Advocate at the University of Pittsburgh IRB Office 1-866-212-2668. 
A copy of this consent form will be given to me, my signature below means that I have 
freely agreed to participate in this research study. 
 
 
 
 
Subject’s Signature Date 
 
 
 
CERTIFICATION OF INFORMED CONSENT 
I certify that I have explained t he nature and pur pose of this research study to the above 
named individual(s), and have discussed the potential benefits and possible risks of  study 
participation. 
Any questions the individual(s) have about this study have be en answered, and we will 
always be available to address future questions as they arise. 
 
 
 
 
Printed Name of Person Obtaining Consent Role in Research Study 
 
 
 
 
Signature of Person Obtaining Consent Date 
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FAMILIAL STUDIES IN CARDIOVASCULAR DISEASE: 
Long Term Follow Up Questionnaire 
 
 
 
 
Part I: General Information 
1. ID Number:   _ 
2.  Current Age:  _ 
3.  Gender: Male or Female 
4.  Ethnicity: 
a.  African-American 
b.  Asian 
c.  Hispanic 
d.  Native American 
e.  White 
f.   Other:   
 
 
5.  What is the highest level of education you have completed: 
a.  Some high school 
b.  Graduated High School/GED 
c.  Some college/vocational school 
d.  Graduated college/vocational school 
e.  Some professional/grad school 
f.  Graduated professional/grad school 
 
 
6.  What is your current marital status: 
a.  Single 
b.  Engaged 
c.  Living Together 
d.  Married 
 
e.  Divorced 
f.  Separated 
g.  Widowed 
 
 
7.  Are you currently employed outside the home? 
a.  Yes – full time 
b.  Yes – part time 
c.  Yes – seasonal 
d.  No - but looking for a job 
e.  No – receive social security 
benefits or disability benefits 
f.  No – not looking for a job 
g.  Retired 
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8.  Which one of the following best describes your current living arrangements? 
a.  Living alone 
b.  Living with spouse/partner 
c.  Living with spouse/partner and children 
d.  Living with parents 
e.  Living with a roommate who is not a family member 
f.   Other:   
 
 
Part II: Diagnosis History 
1. Have you been diagnosed with one of the following heart conditions? 
a.  Brugada Syndrome 
b.  Long QT Syndrome 
c.  None of the above (Skip to question 6, page 3) 
 
 
2.  If you have one of these heart conditions, when did you find out? 
a.  Date:  __/  _/  _ 
b.   Age:   
 
 
3.  If you have one of these heart conditions, how did you find out? 
a.  In a hospital/doctor’s office due to symptoms 
b.  In a hospital/doctor’s office due to abnormal electrocardiogram 
(ECG) 
c.  From screening due to family history 
 
 
4. Did you participate in genetic testing? 
a. No 
b. Yes, and a mutation was found 
c. Yes, but no mutation was found 
 
 
5.  Have you ever experienced any of the following symptoms? Circle all that apply. 
a.  Feeling lightheaded or dizzy 
b.  Fainting 
c.  Irregular heart beat (e.g., skipped or racing) 
d.  Survived cardiac arrest 
 
 
6.  Does anyone in your family have one of the following heart conditions? 
a.  Brugada Syndrome 
b.  Long QT Syndrome 
c.  Neither 
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7.  If yes, how are they related to you? Circle all that apply 
a.  Mother 
b.  Father 
c. Brother 
d.  Sister 
e.  Son 
f.  Daughter 
g. Grandmother 
h.  Grandfather 
i.   Uncle 
j.   Aunt 
k.  Cousin 
l.    Other                                     
 
 
 
 
 
 
 
Part III: Device History 
1. Were you told by a doctor that you might need an implantable cardioverter 
defibrillator (ICD)? 
a.  Yes b.  No (skip to Part IV, page 6) 
 
 
2.  Do you currently have an ICD? 
a.  Yes 
b.  No, but I plan on getting one. (skip to question 6, page 4) 
c.  No and I do not plan on getting one (skip to question 7, page 5) 
d.  No, but I had one in the past (skip to question 8, page 5) 
 
 
3.  If you currently have an ICD or had one in the past, when was it placed? 
a.  Date Placed:   /  /  _ 
b.   Age:   
 
 
4.  If you have an ICD, have you ever been shocked? 
a.  Yes b.  No (skip to question 6, page 4) 
 
 
5.  If you have been shocked: 
a.  How many times have you been shocked? 
i.   Number:   
b.  When were you shocked? List the date for each shock (approximate 
date and month is acceptable) 
i.   Dates:   
  _ 
c.  Did you go to the hospital or doctor’s office when you were shocked? 
i.   Yes, Hospital/Doctor’s Name:   
ii.  No 
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6.  If you have an ICD or plan on getting an ICD, what was the main reason you 
decided to get one? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.  If you do not have an ICD, what was the main reason for choosing not to get 
one? 
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8.  If you had an ICD in the past and no longer have one, why did you decide to get 
it removed? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part IV: Follow Up History 
1. Do you currently see a cardiologist on a regular basis? 
a.  Yes b.  No c.   Plan to do so 
 
 
2.  If yes, please answer the following questions: 
a.  What is the name of your cardiologist? 
i.     _ 
b.  How often do you see them? 
i.      
c.  What is the primary reason for seeing the cardiologist? 
i.     _ 
  _ 
  _ 
 
 
3.  Do you currently see an electrophysiologist? 
a.  Yes b.  No c. Plan to do so 
 
 
4.  If yes, please answer the following questions: 
a.  What is the name of your electrophysiologist? 
i.     _ 
b.  How often do you see them? 
i.     _ 
c.  What is the primary reason for seeing the electrophysiologist? 
i.     _ 
  _ 
  _ 
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